Midatech Pharma


Market Cap£8m

Last Close 8p

Midatech is a drug-delivery specialist focused on re-engineering therapeutics through its technology platforms (MidaSolve, local drug-delivery; Q-Sphera, sustained-release; MidaCore, targeted delivery) to improve biodistribution and delivery.

More Midatech Pharma content >

Investment summary

Midatech is a drug delivery technology company with three key platforms focusing on commercialising and developing products in central nervous system, anti-organ-rejection and brain cancer. The core asset, Q-Sphera, is a sustained release technology; proprietary microspheres that can be tailored to deliver a precise release profile for numerous drugs. The second asset, MidaSolve, is a nanosaccharide technology used to liquefy inherently insoluble drugs to aid local delivery to disease area. Its lead asset, MTX110, is undertaking clinical studies in aggressive brain cancers such as glioblastoma multiforme and diffuse intrinsic pontine glioma, a very rare pediatric cancer. In June 2022, the company received the US FDA fast-track designation for MTX110 in glioblastoma and an EMA orphan drug designation for the treatment of gliomas.

Y/E Dec
Revenue (£m)
PBT (£m)
EPS (p)
P/E (x)
P/CF (x)
2020A 0.3 (9.5) (11.1) (22.92) N/A N/A
2021A 0.6 (6.6) (6.1) (6.78) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A
Industry outlook

The proprietary platforms develop products that address debilitating conditions with significant clinical needs. Applications are expected to be out-licensed for development following proof of concept.

Last updated on 28/09/2022
Content on Midatech Pharma
Midatech Pharma – MTX110 receives ODD from the EMA for gliomas
Healthcare | research Flash note | 21 June 2022
Midatech Pharma – Interim DIPG data to be presented at ISPNO
Healthcare | research Flash note | 13 June 2022
Midatech Pharma – MTX110’s path to market fast-tracked in rGBM
Healthcare | research Flash note | 6 June 2022
View more
Register to receive research on Midatech Pharma as it is published
Share price graph
Balance sheet
Forecast net debt (£m) N/A
Forecast gearing ratio (%) N/A
Price performance
Actual (30.4) (8.6) (69.5)
Relative* (25.8) (3.4) (67.8)
52-week high/low 26.5p/8.0p
*% relative to local index
Key management
Dr Stephen Parker Chairman
Stephen Stamp CEO and CFO